134 related articles for article (PubMed ID: 17324275)
1. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
[TBL] [Abstract][Full Text] [Related]
3. Efalizumab modulates T cell function both in vivo and in vitro.
Koszik F; Stary G; Selenko-Gebauer N; Stingl G
J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
[TBL] [Abstract][Full Text] [Related]
4. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).
Lowes MA; Chamian F; Abello MV; Fuentes-Duculan J; Lin SL; Nussbaum R; Novitskaya I; Carbonaro H; Cardinale I; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Wittkowski KM; Papp K; Garovoy M; Dummer W; Steinman RM; Krueger JG
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19057-62. PubMed ID: 16380428
[TBL] [Abstract][Full Text] [Related]
5. Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
Johnson-Huang LM; Pensabene CA; Shah KR; Pierson KC; Kikuchi T; Lentini T; Gilleaudeau P; Sullivan-Whalen M; Cueto I; Khatcherian A; Hyder LA; Suárez-Fariñas M; Krueger JG; Lowes MA
PLoS One; 2012; 7(2):e30308. PubMed ID: 22348003
[TBL] [Abstract][Full Text] [Related]
6. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
de Groot M; de Rie MA; Bos JD
Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
[No Abstract] [Full Text] [Related]
7. Efalizumab-associated papular psoriasis.
Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
[TBL] [Abstract][Full Text] [Related]
9. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hand and foot psoriasis with emphasis on efalizumab.
Kircik L
Skin Therapy Lett; 2007 Nov; 12(9):4-7. PubMed ID: 18087658
[TBL] [Abstract][Full Text] [Related]
12. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
[TBL] [Abstract][Full Text] [Related]
13. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab.
Chacko M; Weinberg JM
Dermatol Ther; 2007; 20(4):265-9. PubMed ID: 17970891
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
Antonucci A; Bardazzi F; Balestri R; Patrizi A
J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
[TBL] [Abstract][Full Text] [Related]
16. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.
Coffey GP; Stefanich E; Palmieri S; Eckert R; Padilla-Eagar J; Fielder PJ; Pippig S
J Pharmacol Exp Ther; 2004 Sep; 310(3):896-904. PubMed ID: 15190122
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab-induced autoimmune pancytopenia.
Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
[TBL] [Abstract][Full Text] [Related]
20. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
